<DOC>
	<DOCNO>NCT00772551</DOCNO>
	<brief_summary>Evaluation pharmacokinetics safety raltegravir ezetimibe co-administered male female healthy volunteer .</brief_summary>
	<brief_title>Raltegravir Ezetimibe PK Study</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement Male nonpregnant , nonlactating female Between 18 65 year , inclusive Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month study Any significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination Positive blood screen hepatitis B and/or C antibody Positive blood screen HIV1 2 antibody Current recent ( within 3 month ) gastrointestinal disease Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study Exposure investigational drug placebo within 4 week first dose study drug Consumption grapefruit , Seville oranges grapefruit Seville orange contain product within one week first dose study drug duration study Use drug , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 30 day end treatment period Previous allergy constituent pharmaceutical administer trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>